Usefulness of anti-factor VIII IgG ELISA in acquired hemophilia A follow-up.

Autoantibodies Enzyme-Linked Immunosorbent Assay / methods Factor VIII Follow-Up Studies Hemophilia A / diagnosis Humans Immunoglobulin G
Acquired hemophilia A Anti-FVIII IgG ELISA Bethesda assay Coagulation factor VIII Follow-up

Journal

Annals of hematology
ISSN: 1432-0584
Titre abrégé: Ann Hematol
Pays: Germany
ID NLM: 9107334

Informations de publication

Date de publication:
Nov 2022
Historique:
received: 28 03 2022
accepted: 28 08 2022
pubmed: 21 9 2022
medline: 12 10 2022
entrez: 20 9 2022
Statut: ppublish

Résumé

Acquired hemophilia A (AHA) is a rare autoimmune bleeding disorder due to the presence of neutralizing autoantibodies directed against the coagulation factor VIII (FVIII). The reference method to detect and quantify anti-FVIII antibodies is the Bethesda assay (BA), but it presents some limitations such as a lack of sensitivity for low titers of inhibitor and the need for experienced laboratory. A commercially available ELISA detecting anti-FVIII antibodies has demonstrated excellent sensitivity and specificity. The aim of our study was to assess the performance of this ELISA for the detection of anti-FVIII IgG in AHA patients during the follow-up. In total, 11 acquired hemophilia A patients were recruited, and anti-FVIII antibody levels were monitored by BA and ELISA. Anti-FVIII IgG ELISA showed 100% sensitivity and 100% specificity, and it correlated with the BA. Discrepancies observed in 13.3% of cases were consistent with patients' biological evolution. All these data suggest the possible use of anti-FVIII IgG ELISA for both diagnosis and follow-up of AHA patients.

Identifiants

DOI: 10.1007/s00277-022-04972-y PMID: 36125542
pubmed: 36125542
doi: 10.1007/s00277-022-04972-y
pii: 10.1007/s00277-022-04972-y
doi:

Substances chimiques

Autoantibodies 0
Immunoglobulin G 0
Factor VIII 9001-27-8

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2453-2460

Informations de copyright

© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Références

Tiede A, Collins P, Knoebl P et al (2020) International recommendations on the diagnosis and treatment of acquired hemophilia A. Haematologica 105:1791–1801. https://doi.org/10.3324/haematol.2019.230771
doi: 10.3324/haematol.2019.230771 pubmed: 32381574 pmcid: 7327664
Knoebl P, Marco P, Baudo F et al (2012) Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). J Thromb Haemost JTH 10:622–631. https://doi.org/10.1111/j.1538-7836.2012.04654.x
doi: 10.1111/j.1538-7836.2012.04654.x pubmed: 22321904
Batty P, Moore GW, Platton S et al (2015) Diagnostic accuracy study of a factor VIII ELISA for detection of factor VIII antibodies in congenital and acquired haemophilia A. Thromb Haemost 114:804–811. https://doi.org/10.1160/TH14-12-1062
doi: 10.1160/TH14-12-1062 pubmed: 26063073
Tiede A, Klamroth R, Scharf RE et al (2015) Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study. Blood 125:1091–1097. https://doi.org/10.1182/blood-2014-07-587089
doi: 10.1182/blood-2014-07-587089 pubmed: 25525118 pmcid: 4326770
Tiede A, Alberio L (2020) The art of detecting antibodies against factor VIII. Hamostaseologie 40:485–490. https://doi.org/10.1055/a-1223-3353
doi: 10.1055/a-1223-3353 pubmed: 32961576
Federici AB, Budde U, Castaman G et al (2013) Current diagnostic and therapeutic approaches to patients with acquired von Willebrand syndrome: a 2013 update. Semin Thromb Hemost 39:191–201. https://doi.org/10.1055/s-0033-1334867
doi: 10.1055/s-0033-1334867 pubmed: 23397553
Tiede A, Werwitzke S, Scharf R (2014) Laboratory Diagnosis of acquired hemophilia A: Limitations, consequences, and challenges. Semin Thromb Hemost 40:803–811. https://doi.org/10.1055/s-0034-1390004
doi: 10.1055/s-0034-1390004 pubmed: 25299927
Kitchen S, Jennings I, Preston F et al (2009) Interlaboratory variation in factor VIII: C inhibitor assay results is sufficient to influence patient management: data from the UK National Quality External Assessment Scheme for Blood Coagulation. Semin Thromb Hemost 35:778–785. https://doi.org/10.1055/s-0029-1245110
doi: 10.1055/s-0029-1245110 pubmed: 20169514
Werwitzke S, Geisen U, Nowak-Göttl U et al (2016) Diagnostic and prognostic value of factor VIII binding antibodies in acquired hemophilia A: data from the GTH-AH 01/2010 study. J Thromb Haemost JTH 14:940–947. https://doi.org/10.1111/jth.13304
doi: 10.1111/jth.13304 pubmed: 26988717
Kruse-Jarres R, Kempton CL, Baudo F et al (2017) Acquired hemophilia A: updated review of evidence and treatment guidance. Am J Hematol 92:695–705. https://doi.org/10.1002/ajh.24777
doi: 10.1002/ajh.24777 pubmed: 28470674
Huth-Kühne A, Baudo F, Collins P et al (2009) International recommendations on the diagnosis and treatment of patients with acquired hemophilia A. Haematologica 94:566–575. https://doi.org/10.3324/haematol.2008.001743
doi: 10.3324/haematol.2008.001743 pubmed: 19336751 pmcid: 2663620
Collins PW, Hirsch S, Baglin TP et al (2007) Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors’ Organisation. Blood 109:1870–1877. https://doi.org/10.1182/blood-2006-06-029850
doi: 10.1182/blood-2006-06-029850 pubmed: 17047148
Sahud MA, Pratt KP, Zhukov O et al (2007) ELISA system for detection of immune responses to FVIII: a study of 246 samples and correlation with the Bethesda assay. Haemophilia 13:317–322. https://doi.org/10.1111/j.1365-2516.2007.01450.x
doi: 10.1111/j.1365-2516.2007.01450.x pubmed: 17498082
Cannavò A, Valsecchi C, Garagiola I et al (2017) Nonneutralizing antibodies against factor VIII and risk of inhibitor development in severe hemophilia A. Blood 129:1245–1250. https://doi.org/10.1182/blood-2016-06-720086
doi: 10.1182/blood-2016-06-720086 pubmed: 28034891
Dazzi F, Tison T, Vianello F et al (1996) High incidence of anti-FVIII antibodies against non-coagulant epitopes in haemophilia A patients: a possible role for the half-life of transfused FVIII. Br J Haematol 93:688–693. https://doi.org/10.1046/j.1365-2141.1996.d01-1705.x
doi: 10.1046/j.1365-2141.1996.d01-1705.x pubmed: 8652395
Mondorf W, Ehrenforth S, Vigh Z et al (1994) Screening of F.VIII: C antibodies by an enzyme-linked immunosorbent assay. Vox Sang 66:8–13. https://doi.org/10.1111/j.1423-0410.1994.tb00269.x
doi: 10.1111/j.1423-0410.1994.tb00269.x pubmed: 8146988
Blanco AN, Peirano AA, Grosso SH et al (2000) An ELISA system to detect anti-factor VIII antibodies without interference by lupus anticoagulants. Preliminary data in hemophilia A patients. Haematologica 85:1045–1050
pubmed: 11025595
Martin PG, Sukhu K, Chambers E, Giangrande PL (1999) Evaluation of a novel ELISA screening test for detection of factor VIII inhibitory antibodies in haemophiliacs. Clin Lab Haematol 21:125–128. https://doi.org/10.1046/j.1365-2257.1999.00194.x
doi: 10.1046/j.1365-2257.1999.00194.x pubmed: 10342072
Scandella D, Mattingly M, Prescott R (1993) A recombinant factor VIII A2 domain polypeptide quantitatively neutralizes human inhibitor antibodies that bind to A2. Blood 82:1767–1775
doi: 10.1182/blood.V82.6.1767.1767
Klinge J, Auerswald G, Budde U et al (2001) Detection of all anti-factor VIII antibodies in haemophilia A patients by the Bethesda assay and a more sensitive immunoprecipitation assay. Haemoph Off J World Fed Hemoph 7:26–32. https://doi.org/10.1046/j.1365-2516.2001.00456.x
doi: 10.1046/j.1365-2516.2001.00456.x
Trossaert M, Graveleau J, Thiercelin-Legrand M-F et al (2019) The factor VIII:C/VWF: Ag ratio as a useful tool to predict relapse in patients with acquired haemophilia A: a retrospective cohort study. Haemoph Off J World Fed Hemoph 25:527–534. https://doi.org/10.1111/hae.13752
doi: 10.1111/hae.13752
Tiede A, Hofbauer CJ, Werwitzke S et al (2016) Anti-factor VIII IgA as a potential marker of poor prognosis in acquired hemophilia A: results from the GTH-AH 01/2010 study. Blood 127:2289–2297. https://doi.org/10.1182/blood-2015-09-672774
doi: 10.1182/blood-2015-09-672774 pubmed: 26912467
Tay L, Duncan E, Singhal D et al (2009) Twelve years of experience of acquired hemophilia A: trials and tribulations in South Australia. Semin Thromb Hemost 35:769–777. https://doi.org/10.1055/s-0029-1245109
doi: 10.1055/s-0029-1245109 pubmed: 20169513
Knoebl P, Thaler J, Jilma P et al (2021) Emicizumab for the treatment of acquired hemophilia A. Blood 137:410–419. https://doi.org/10.1182/blood.2020006315
doi: 10.1182/blood.2020006315 pubmed: 32766881

Auteurs

Albain Chansavang (A)

Biological Hematology Department, Assistance Publique Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Paris, France.

Aurélien Philippe (A)

Biological Hematology Department, Assistance Publique Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Paris, France.

Ines Bozinovic (I)

Biological Hematology Department, Assistance Publique Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Paris, France.

Khalil Ben Hadj Ali (K)

Biological Hematology Department, Assistance Publique Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Paris, France.

David Smadja (D)

Biological Hematology Department, Assistance Publique Hôpitaux de Paris, Hôpital Européen Georges Pompidou; INSERM, UMR-S1140, Innovative Therapies in Haemostasis; Université de Paris-Cité, Paris, France.

Dominique Helley (D)

Biological Hematology Department, Assistance Publique Hôpitaux de Paris, Hôpital Européen Georges Pompidou; INSERM, UMR-S970 - Paris Cardiovacasular Research Center (PARCC); Université de Paris Cité, Paris, France.

Luc Darnige (L)

Biological Hematology Department, Assistance Publique Hôpitaux de Paris, Hôpital Européen Georges Pompidou; INSERM, UMR-S1140, Innovative Therapies in Haemostasis, Paris, France.

Laetitia Mauge (L)

Biological Hematology Department, Assistance Publique Hôpitaux de Paris, Hôpital Européen Georges Pompidou; INSERM, UMR-S970 - Paris Cardiovacasular Research Center (PARCC); Université de Paris Cité, Paris, France. laetitia.mauge@aphp.fr.
ORCID: 0000-0002-3946-2312

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Autoanticorps › Usefulness of anti-factor VIII IgG ELISA in...
questionsmedicales.fr › Techniques d'investigation › Techniques de sonde moléculaire › Dosage immunologique › Techniques d'immunoadsorption › Test ELISA › Usefulness of anti-factor VIII IgG ELISA in...
questionsmedicales.fr › Facteurs biologiques › Facteurs de la coagulation sanguine › Facteur VIII › Usefulness of anti-factor VIII IgG ELISA in...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études de suivi › Usefulness of anti-factor VIII IgG ELISA in...
questionsmedicales.fr › Malformations et maladies congénitales, héréditaires et néonatales › Maladies génétiques congénitales › Troubles héréditaires de la coagulation sanguine › Hémophilie A › Usefulness of anti-factor VIII IgG ELISA in...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Usefulness of anti-factor VIII IgG ELISA in...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Isotypes des immunoglobulines › Immunoglobuline G › Usefulness of anti-factor VIII IgG ELISA in...